NanoViricides NNVC 深 沪
等待开盘 04-01 09:30:00 美东时间
0.9121
+0.042
+4.84%
华盛通- 最 高0.9494
- 今 开0.92
- 成交量 6.65万股
- 最 低 0.9037
- 昨 收 0.87
- 总市值 1969.68万
- 52周最高 2.2299
- 市盈率 静 --
- 换手率 0.31%
- 52周最低 0.85
- 委 比 1.61%
- 总股本 2159.50万
- 历史最高 151.80
- 量 比 0.43
- 振 幅 5.25%
- 历史最低 0.85
- 每 手 1
- 风险率 0.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NanoViricides To Launch Phase II Trial Of NV-387 For Monkeypox Clade I In DRC, Targeting Pandemic-Ready Treatment
NanoViricides, Inc. (NYSE:NNVC) (the "Company") today announced that a Phase II Clinical Trial of Monkeypox Treatment by NV-387 is expected to begin soon in the Democratic Republic of Congo (DRC).Clinical Trial Site
38分钟前
NanoViricides to present at NIBA’s 152nd Investment Conference
NanoViricides to present at NIBA’s 152nd Investment Conference NanoViricides will present at NIBA’s 152nd Investment Conference in Fort Lauderdale, Florida on March 12, 2026. The company said its presentation is scheduled for 11:50 a.m. ET. Source: ACCESS Newswire . Disclaimer: This news brief was c
03-11 20:31
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Impact BioMedical (AMEX:IBO) shares rose 70.2% to $0.7 during Thursday...
03-05 20:05
Nanoviricides Q2 EPS $(0.11) Beats $(0.14) Estimate
Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 21.43 percent increase over losses of $(0.14) per share from the
02-18 06:02
美股机会日报 | 降息预期升温！美国1月CPI年率创去年5月来新低；净利、指引双超预期！应用材料盘前涨超10%
降息预期升温！美国1月CPI年率创去年5月来新低；就任板上钉钉？特朗普政府正筹备沃什美联储主席提名；净利、指引双超预期！应用材料盘前涨超10%；有机构警告比特币或下探5万美元>>
02-13 21:58
NanoViricides Files Application For Orphan Drug Designation For NV-387 To Treat Measles
NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine
02-10 21:43
NanoViricides Files Orphan Drug Designation Application for Measles Treatment with FDA
NanoViricides Files Orphan Drug Designation Application for Measles Treatment with FDA NanoViricides Inc., a publicly traded clinical stage company specializing in broad-spectrum antivirals, announced that it has filed an application with the US FDA Office of Orphan Products Development (OOPD) for O
02-10 21:31
NanoViricides President Unveils Breakthrough Antiviral Technology in Mission Matters Interview
NanoViricides President Unveils Breakthrough Antiviral Technology in Mission Matters Interview NanoViricides, Inc. President Dr. Anil R. Diwan was recently interviewed on the Mission Matters Podcast by Adam Torres. During the discussion, Dr. Diwan outlined the company's mission to revolutionize anti
02-02 21:32
NanoViricides Signs Master Services Agreement With Only Orphans Cote To Advance Orphan Drug Strategy For NV-387
NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology
2025-12-01 21:35
BRIEF-anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
Dec 1 (Reuters) - NanoViricides, Inc NNVC.A: NANOVIRICIDES: SIGNED MASTER SERVICES AGREEMENT WITH ONLY ORPHANS COTE FOR ORPHAN DRUG STRATEGY OF NV-387 FOR TREATMENT OF MPOX, SMALLPOX, & MEASLES Source...
2025-12-01 21:33
